1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
暂无分享，去创建一个
G. Daniels | D. Rischin | A. Haydon | R. Kudchadkar | F. Collichio | M. Migden | N. Khushalani | A. Hill | M. Fury | P. Bommareddy | C. Andreu-Vieyra | M. Alamgeer | D. Brungs | W. Chai-Ho | S. Bowyer | A. D. Colevas | J. Lutzky | S. He | P. Sheladia | J. Lee